Alligator Bioscience AB (OSTO:ATORX) Cash-to-Debt : 0.69 (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Alligator Bioscience AB Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Alligator Bioscience AB's cash to debt ratio for the quarter that ended in Mar. 2025 was 0.69.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Alligator Bioscience AB couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2025.

The historical rank and industry rank for Alligator Bioscience AB's Cash-to-Debt or its related term are showing as below:

OSTO:ATORX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.69 Med: 12.11 Max: No Debt
Current: 0.69

During the past 11 years, Alligator Bioscience AB's highest Cash to Debt Ratio was No Debt. The lowest was 0.69. And the median was 12.11.

OSTO:ATORX's Cash-to-Debt is ranked worse than
80.78% of 1483 companies
in the Biotechnology industry
Industry Median: 7.57 vs OSTO:ATORX: 0.69

Alligator Bioscience AB Cash-to-Debt Historical Data

The historical data trend for Alligator Bioscience AB's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Alligator Bioscience AB Cash-to-Debt Chart

Alligator Bioscience AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

8.56

28.57

3.97

4.11

1.48

Alligator Bioscience AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash-to-Debt	Get a 7-Day Free Trial															2.87	6.57	4.80	1.48	0.69

Competitive Comparison of Alligator Bioscience AB's Cash-to-Debt

For the Biotechnology subindustry, Alligator Bioscience AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alligator Bioscience AB's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Alligator Bioscience AB's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Alligator Bioscience AB Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Alligator Bioscience AB's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	64.31	/	(10.097	+	33.475)
	=	1.48

Alligator Bioscience AB's Cash to Debt Ratio for the quarter that ended in Mar. 2025 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	28.853	/	(9.478	+	32.384)
	=	0.69

Alligator Bioscience AB (OSTO:ATORX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Alligator Bioscience AB Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Alligator Bioscience AB's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Alligator Bioscience AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alligator Bioscience AB (OSTO:ATORX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

0RK9:UK 7AL0:Germany

Address

Medicon Village, Scheeletorget 1, Lund, SWE, 223 81

Website

https://www.alligatorbioscience.se

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. Its drug candidate mitazalimab, is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 18-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1.

Alligator Bioscience AB Headlines

No Headlines